Exhibit 99.4

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

On May 18, 2026, the Company entered into a binding Scheme Implementation Deed (SID) under which the Company will acquire all of the issued shares and listed options of European Lithium Ltd. (“European Lithium” or “EUR”) by way of two interdependent schemes of arrangement under Australian law (the “EUR Transaction”). Completion of the EUR Transaction is conditional upon a number of items, including, without limitation, the approval of the shareholders of European Lithium which is scheduled to occur on October 22, 2026. The EUR Transaction is expected to be completed in November 2026.

 

On July 3, 2026, the Company entered into a deed to amend the SID with the principal changes being:

 

●EUR Shareholders and EUR Optionholders holding 50,000 or fewer EUR Shares or EUR Options (as applicable) on the record date will be given the option to participate in a sale facility whereby the CRML shares they would otherwise be entitled to under the Schemes will be sold on market by a sale agent and the EUR Shareholder or EUR Optionholder (as applicable) will instead receive the net sale proceeds of such sale;

 

●the CRML shares issued as Scheme consideration will be issued directly to EUR Shareholders and EUR Optionholders, rather than utilising a CHESS Depository Interest (CDI) structure as had been initially contemplated (and expressly reserved for further determination) under the terms of the May SID.

 

On August 19, 2026, the Company entered into a second deed to amend the SID with the principal changes being the introduction of a floating Share Scheme Transaction Ratio, subject to a cap and collar, replacing the previous fixed ratio of 0.035 New CRML Shares for each EUR Share whereby:

 

●the Share Scheme Transaction Ratio will be determined by reference to the Scheme VWAP, being the average daily VWAP of CRML Shares on NASDAQ over the 20 consecutive NASDAQ Trading Days ending on the second NASDAQ Trading Day before the Share Scheme Meeting;

 

●where the Scheme VWAP is at or below the Floor Price (US$8.00), the Maximum Share Scheme Transaction Ratio of 0.045 will apply;

 

●where the Scheme VWAP is at or above the Ceiling Price of US$16.00, the Minimum Share Scheme Transaction Ratio of 0.025 will apply; and

 

●where the Scheme VWAP is between US$8.00 and US$16.00, the Share Scheme Transaction Ratio will be calculated in accordance with the formula set out in the amended SID, with the ratio adjusting on a linear basis between 0.045 and 0.025.

 

The unaudited pro forma condensed combined balance sheet as of June 30, 2026 combines the audited historical consolidated balance sheet of CRML as of June 30, 2026 with the audited historical consolidated balance sheet of European Lithium as of June 30, 2026, giving effect to the EUR Transaction as if it had been consummated as of that date.

 

The unaudited pro forma condensed combined statement of operations for the fiscal year ended June 30, 2026 combines the audited historical consolidated statement of operations of CRML for the fiscal year ended June 30, 2026, and the audited historical consolidated financial statements of EUR for the fiscal year ended June 30, 2026, giving effect to the EUR Transactions as if it had been consummated as of July 1, 2025, the first day of the earliest period presented.

 

The historical financial information has been adjusted to give pro forma effect to events that relate to material financing and acquisition transactions consummated or intended after June 30, 2026 which consist of the EUR Transaction. The adjustments presented on the unaudited pro forma condensed combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding of the combined company.

 

The historical financial consolidated statements of CRML, and EUR have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The condensed combined pro forma financial information is prepared on an IFRS basis and is presented in US Dollars (“USD”), the reporting currency used by the Company.

 

The historical financial statements of EUR were originally reported using Australian Dollars (“AUD”) and have been translated into USD to conform to the reporting currency of CRML.

 

 

 

The unaudited pro forma condensed combined financial information is for illustrative purposes only. The actual financial results may have differed had the companies been combined during the periods presented. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies been combined or of the future results that the combined company will experience.

 

In connection with the EUR Transaction, the acquisition of EUR is an asset acquisition accounted for under IFRS 2 and as a result the 7.5% interest in Tanbreez held by EUR will eliminate the non-controlling interest held by CRML in Tanbreez as an equity transaction under IFRS 10.23 and accounted for as a consolidation in accordance with IFRS 10. In accordance with IFRS 10, changes in a parent’s ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. The subsequent increase in CRML’s ownership interest via the EUR Transaction is reflected as an equity transaction; no gain or loss is recognized in the statement of operations, and the carrying amounts of the controlling interest and the non-controlling interest (“NCI”) are adjusted, reducing the NCI to zero to reflect CRML’s 100% ultimate ownership of Tanbreez.

 

This information should be read together with the following:

 

  ● the historical audited consolidated financial statements of CRML as of June 30, 2026 and 2025 and for the fiscal year ended June 30, 2026, 2025 and 2024;
     
  ● the historical audited consolidated financial statements of EUR as of and for the fiscal year ended June 30, 2026 and 2025.

 

Anticipated Accounting Treatment

 

EUR Transaction

 

In connection with the EUR Transaction, the acquisition of EUR will be accounted for as a consolidation, in accordance with IFRS10. CRML will acquire 100% of EUR and, as a result the remaining 7.5% interest in Tanbreez held by EUR, will bring CRML’s total ownership of Tanbreez to 100%. In accordance with IFRS 10.23, changes in a parent’s ownership interest in a subsidiary that do not result in a loss of control are accounted for strictly as equity transactions (i.e., transactions with owners in their capacity as owners).

 

Consequently, the acquisition of the remaining 7.5% interest via the EUR Transaction will not result in the recognition of a gain or loss in the statement of operations. Instead, the transaction will adjust the carrying amounts of the controlling interest and reduce the NCI balance to zero, reflecting CRML’s ultimate 100% ownership of Tanbreez.

 

Accounting Acquirer Determination for EUR Transaction

 

CRML was determined to be the accounting acquirer in the EUR Transaction under IFRS 10 and IFRS 3. While the application of IFRS 3 involves a higher level of judgement, an evaluation of the relative facts and circumstances favored CRML as the acquirer, specifically:

 

  ● existing CRML shareholders are expected to hold a majority of the ordinary shares of the combined company following the EUR Transaction. Under the minimum consideration scenario CRML is anticipated to hold approximately 67% and EUR 33% and under the maximum consideration scenario CRML is anticipated to hold approximately 53% and EUR 47%;

 

  ● the board of directors of CRML following the EUR Transaction is expected to remain identical to the board of directors of CRML prior to the EUR Transactions; and

 

  ● the senior management of CRML following the EUR Transaction is expected to remain identical to the senior management CRML prior to the EUR Transactions.

 

Accordingly, EUR is treated as the accounting acquiree.

 

Asset Acquisition Classification of Stage 2 Acquisition and EUR transaction

 

In accordance with IFRS 3, the EUR Transaction are accounted for as an asset acquisition rather than a business combination, because EUR lack the substantive inputs and processes required to meet the definition of a business:

 

  ● Input –EUR inputs are primarily cash on hand, investment in Tanbreez and investment in CRML.

 

  ● Process –EUR has no significant process in place.

 

  ● Output –EUR’s primary output is linked to its interest in Tanbreez and its CRML investment.

 

Because the EUR transaction does not constitute a business combination and the purchase consideration is settled via the issuance of equity instruments, the transaction falls within the scope of IFRS 2 (Share-based Payment) as an equity-settled asset acquisition.

 

2

 

 

Measurement Basis and Asset/Equity Recognition

 

In accordance with IFRS 2, the transaction is measured based on the fair value of the identifiable assets acquired and liabilities assumed at the acquisition date. CRML recognizes these identifiable items at their acquisition-date fair values, including property, plant, and equipment (PP&E), cash and cash equivalents, and other investments. Equity instruments issued by the Company are recognized as an increase in equity, measured by reference to the fair value of the net assets acquired. Because IFRS 3 does not apply, no goodwill is recognized, total consideration is entirely allocated to the identifiable assets and liabilities based on their relative fair values, and transaction costs are capitalized as part of the initial asset cost basis. 

 

EUR Transaction

 

Reciprocal Shareholding and Treasury Share Reclassification (IAS 32)

 

Prior to the closing of the EUR Transaction, EUR will hold a historical investment in CRML. While this investment is initially recognized at fair value as part of the assets acquired via the transaction, under IAS 32 (Financial Instruments: Presentation), an entity is prohibited from recognizing its own equity instruments as a financial asset. Accordingly, the historical CRML shares to be acquired from EUR will be immediately reclassified as treasury shares and presented as a deduction from equity within the condensed combined financial statements, eliminating the reciprocal investment asset against equity.

 

Replacement Share-Based Payment Awards

 

As part of the EUR Transaction, the Company will replace existing share-based payment arrangements held by key management personnel (KMPs) of EUR with new equity-settled awards over the shares of CRML.

 

While the transaction is an asset acquisition outside the scope of IFRS 3, the allocation and modification principles of IFRS 2 are applied to evaluate these replacement awards. The grant-date fair value of the replacement awards is allocated between historical acquisition consideration and post-acquisition employee compensation based on the proportion of the vesting period completed at the acquisition date:

 

  ● Pre-Acquisition Service Portion: The portion of the fair value attributable to service periods completed prior to the acquisition is capitalized and included in the cost basis of the assets acquired.

 

  ● Post-Acquisition Service Portion: The portion attributable to remaining vesting periods is recognized as employee compensation expense over the prospective post-acquisition service period.

 

The replacement of these awards constitutes a modification under IFRS 2. The Company measures the fair value of the original awards immediately before the replacement and compares it to the fair value of the new awards at the grant date. Any incremental fair value granted is recognized as additional employee compensation expense over the remaining vesting period. The Company recognizes, at minimum, the grant-date fair value of the original awards, provided the original vesting conditions are met.  

 

3

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

AS OF JUNE 30, 2026

 

    CRML
(Historical)
    EUR
(Historical)
    Combined
before
adjustments
    EUR
Transaction
Accounting
Adjustments-Min
      Pro Forma
Combined
    EUR
Transaction
Accounting
Adjustments-Max
      Pro Forma
Combined
 
ASSETS                                                            
Current assets                                                            
Cash and cash equivalents   $ 102,476,578     $ 204,162,127     $ 306,638,705     $ -        $ 306,638,705     $ -        $ 306,638,705  
                                                           
Trade and other receivables    

1,206,085

      1,284,358       2,490,443       -          2,490,443       -          2,490,443  
Prepaid expenses     938,440       43,690       982,130       -          982,130       -          982,130  
Indemnification asset     -        1,181,164       1,181,164       -          1,181,164       -          1,181,164  
Short term loans receivable     -        6,621,899       6,621,899       (5,667,442 ) D     954,457       (5,667,442 ) D     954,457  
Derivative asset     -        4,583,779       4,583,779       -          4,583,779       -          4,583,779  
Total current assets     104,621,103       217,877,017       322,498,120       (5,667,442 )       316,830,678       (5,667,442 )       316,830,678  
Non-current assets                                                            
Restricted cash and other deposits     15,359,960       39,237       15,399,197       -          15,399,197       -          15,399,197  
Property and plant and equipment, net     16,755,765       1,019       16,756,784       -          16,756,784       -          16,756,784  
Inventory, net     15,800,000        -       15,800,000       -          15,800,000       -          15,800,000  
Deferred exploration and evaluation expenditure     343,957,052       -        343,957,052       -          343,957,052       -          343,957,052  
Investment in joint venture     7,423,067       -        7,423,067       -          7,423,067       -          7,423,067  
Listed and unlisted investments     -       21,782,165       21,782,165       -          21,782,165       -          21,782,165  
Investment in associate     -       31,328,480       31,328,480       -          31,328,480       -          31,328,480  
Investment in associate -Tanbreez      -       7,177,119       7,177,119       16,892,021   A     -       16,892,021   A     -  
                              (24,069,140 ) C             (24,069,140 ) C        
Investment in associate -CRML     -       466,444,026       466,444,026       262,137,382   A     -       (102,153,322 ) A     -  
                              (728,581,408 ) B             (364,290,704 ) B        
Right of use asset     11,502       -       11,502        -         11,502       -          11,502  
Long term loans receivable      -       803,432       803,432       (803,432 ) D     -       (803,432 ) D     -  
Total non-current assets     399,307,346       527,575,478       926,882,824       (474,424,577 )       452,458,247       (474,424,577 )       452,458,247  
Total assets   $ 503,928,449     $ 745,452,495     $ 1,249,380,944     $ (480,092,019 )     $ 769,288,925     $ (480,092,019 )     $ 769,288,925  
                                                             
LIABILITIES                                                            
Current liabilities                                                            
Trade and other payables   $ 19,210,789       2,136,546       21,347,335       -          21,347,335       -          21,347,335  
Provisions     106,392       -       106,392       -          106,392       -          106,392  
Lease liability     6,244       1,315       7,559       -          7,559       -          7,559  
Funding from related party     5,671,129       -        5,671,129       (5,671,129 ) D     -       (5,671,129 ) D     -  
Warrants liability     95,067,012       -        95,067,012       -          95,067,012       -          95,067,012  
                                                     
Total current liabilities     120,061,566       2,137,861       122,199,427       (5,671,129 )       116,528,298       (5,671,129 )       116,528,298  
Non-current liabilities                                                            
Funding from related party     803,955       -        803,955       (803,955 ) D     -       (803,955 ) D     -  
Offtake prepayment     15,000,000       -        15,000,000       -         15,000,000        -         15,000,000  
Lease liability     7,614       460       8,074        -         8,074        -         8,074  
Deferred tax liability      -       1,261,437       1,261,437        -         1,261,437        -         1,261,437  
Total non-current liabilities     15,811,569       1,261,897       17,073,466       (803,955 )       16,269,511       (803,955 )       16,269,511  
Total liabilities     135,873,135       3,399,758       139,272,893       (6,475,084 )       132,797,809       (6,475,084 )       132,797,809  
                                                             
Net Assets     368,055,314       742,052,737       1,110,108,051       (473,616,935 )       636,491,116       (473,616,935 )       636,491,116  
                                                             
EQUITY                                                            
Share capital     629,774,711       66,474,147       696,248,858       954,607,993   A     1,650,856,851       635,836,974   A     1,332,085,832  
Share premium     -        -       -        -         -        -         -  
Unissued Capital     45,734,183        -       45,734,183        -         45,734,183        -         45,734,183  
Treasury shares      -        -       -       (728,581,408 ) B     (728,581,408 )     (364,290,704 ) B     (364,290,704 )
Reserves     97,532,461       (7,039,938 )     90,492,523       7,039,938   A     97,536,671       7,039,938   A     97,536,671  
                              4,210   D             4,210   D        
Accumulated deficit     (429,055,181 )     682,618,529       253,563,348       (682,618,529 ) A     (429,055,181 )     (728,138,214 ) A     (474,574,866 )
Non controlling interest     24,069,140       (1 )     24,069,139       1   A     -       1   A     -  
                              (24,069,140 ) C             (24,069,140 ) C        
                                                             
Total equity   $ 368,055,314     $ 742,052,737     $ 1,110,108,051     $ (473,616,935 )     $ 636,491,116     $ (473,616,935 )     $ 636,491,116  
 

4

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FISCAL YEAR ENDED JUNE 30, 2026

 

   CRML
(Historical)
   EUR
(Historical)
   Tanbreez
(July 1, 2025 through April 29, 2026)
   Combined before adjustments   EUR Transaction Accounting Adjustments -Min      Pro Forma Combined   EUR Transaction Accounting Adjustments -Max      Pro Forma Combined 
                                       
Other income  $1,888,145    5,365,024    4,982    7,258,151    -       7,258,151    -       7,258,151 
Fair value gain   -    4,508,212         4,508,212    -       4,508,212    -       4,508,212 
Foreign exchange   190,100    (10,767,675)   (2,143,745)   (12,721,320)   -       (12,721,320)   -       (12,721,320)
Salaries and wages   (42,169)   (392,789)   (10,874)   (445,832)   -       (445,832)   -       (445,832)
Consultants and professional services expenses   (10,618,428)   (5,258,476)   (120,576)   (15,997,480)   -       (15,997,480)   -       (15,997,480)
Travel and entertainment   (324,815)   (188,597)   (23,038)   (536,450)   -       (536,450)   -       (536,450)
Directors’ fees   (1,070,833)   -    -    (1,070,833)   -       (1,070,833)   -       (1,070,833)
Merger expenses   (2,535,670)   (829,954)   -    (3,365,624)   -       (3,365,624)   -       (3,365,624)
Listing expense   (15,500,000)   -    -    (15,500,000)   -       (15,500,000)   -       (15,500,000)
Compliance and regulatory fees   (1,792,127)   (576,525)   (236,327)   (2,604,979)   -       (2,604,979)   -       (2,604,979)
Administration expenses   (380,269)   (945,090)   (4,480)   (1,329,839)   -       (1,329,839)   -       (1,329,839)
Promotion, IR and PR expenses   (1,468,606)   (174,629)   -    (1,643,235)   -       (1,643,235)   -       (1,643,235)
Occupancy   -    (1,460)   -    (1,460)   -       (1,460)   -       (1,460)
Insurance   (1,653,497)   (122,932)   -    (1,776,429)   -       (1,776,429)   -       (1,776,429)
Finance costs   (14,986,995)   (3,030,020)   (30,383)   (18,047,398)   -       (18,047,398)   -       (18,047,398)
Depreciation expense   (19,443)   (1,498)   (12,378)   (33,319)   -       (33,319)   -       (33,319)
Share of net losses of JV accounted for using the equity method   (1,054,949)   (87,638,533)   -    (88,693,482)   87,638,533   BB   -    87,638,533   BB   - 
                        1,054,949   EE        1,054,949   EE     
Share of net losses of associate   (70,682)   -    -    (70,682)   -       (70,682)   -       (70,682)
Depreciation expense – leased assets   (10,953)   (17,634)   -    (28,587)   -       (28,587)   -       (28,587)
Impairment of investments in associate   (279,386)   (110,521,982)   -    (110,801,368)   110,521,982   BB   (279,386)   110,521,982   BB   (279,386)
Exploration expenditure expensed   (272,807)   (124,702)   -    (397,509)   -       (397,509)   -       (397,509)
Loss on fair value of warrants   (120,872,053)   -    -    (120,872,053)   -       (120,872,053)   -       (120,872,053)
Gain on Derecognition of Warrants   10,918,539    -    -    10,918,539    -       10,918,539    -       10,918,539 
Gain (Loss) on Extinguishment of Liability   (2,170,000)   (69,924)   -    (2,239,924)   -       (2,239,924)   -       (2,239,924)
Net loss on disposals and deemed disposal of shares   -    (13,795,642)   -    (13,795,642)   13,795,642   BB   -    13,795,642   BB   - 
Gain on Deconsolidation of CRML   -    864,396,188    -    864,396,188    (864,396,188)  BB   -    (864,396,188)  BB   - 
Gain on Deconsolidation – Recycling of FX Translation Reserve   -    1,749,399    -    1,749,399    (1,749,399)  BB   -    (1,749,399)  BB   - 
CRML Expenses (pre-deconsolidation)   -    (10,641,602)   -    (10,641,602)   10,641,602   BB   -    10,641,602   BB   - 
Exploration Expenditure Impairment   -    (561,688)   -    (561,688)   -       (561,688)   -       (561,688)
Share based payments to directors and management   (65,994,203)   (7,190,330)   -    (73,184,533)   (35,664,210)  CC   (101,658,413)   (42,270,249)  CC   (108,264,452)
                        7,190,330   CC        7,190,330   CC     
Gain on fair value of financial assets through profit or loss        8,190,534    -    8,190,534    -       8,190,534    -       8,190,534 
Day 1 loss on acquisition   -    -    -    -    -       -    (45,519,685)  DD   (45,519,685)
Impairment   -    473,227    -    473,227    -       473,227    -       473,227 
Other expenses   (122,668)   62,937    (24,615)   (84,346)   -       (84,346)   -       (84,346)
Profit/(loss) before income tax   (228,243,769)   631,893,839    (2,601,434)   401,048,636    (670,966,759)      (267,316,689)   (723,092,483)      (322,043,847)
Income tax expense   -    (1,240,641)        (1,240,641)           (1,240,641)           (1,240,641)
Profit/(loss) after tax   (228,243,769)   630,653,198    (2,601,434)   399,807,995    (670,966,759)      (268,557,330)   (723,092,483)      (323,284,488)
                                               
Net income (loss) attributed to non-controlling interest   (44,259)   (4,378,424)        (4,422,683)   4,422,683.00   AA   -    4,422,683   AA   - 
Net income (loss) attributed to CRML  $(228,199,510)   635,031,622    (2,601,434)   404,230,678    (675,389,442)      (268,557,330)   (727,515,166)      (323,284,488)
                                               
Other comprehensive income, net of income tax                                              
Items that may be reclassified to profit or loss                                              
Exchange differences on translation of foreign operations   (9,082,726)   (36,150,801)        (45,233,527)   -       (45,233,527)   -       (45,233,527)
Other comprehensive (loss)/profit for the period, net of income tax   (9,082,726)   (36,150,801)   -    (45,233,527)   -       (45,233,527)   -       (45,233,527)
                                               
Total comprehensive (loss)/profit for the period  $(237,326,495)   594,502,397    (2,601,434)   354,574,468    (670,966,759)      (313,790,857)   (723,092,483)      (368,518,015)
                                               
Pro forma weighted average number of shares outstanding - basic and diluted                               127,218,426            167,362,052 
Pro forma earnings per share - basic and diluted                              $(2.11)          $(1.93)
5

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

 

Note 1 — Description of the Business Combination

 

On May 18, 2026, the Company entered into a binding Scheme Implementation Deed (“SID”) under which the Company will acquire all of the issued shares and listed options of European Lithium Ltd. (“European Lithium” or “EUR”) by way of two interdependent schemes of arrangement under Australian law (the “EUR Transaction”). Completion of the EUR Transaction is conditional upon a number of items, including, without limitation, the approval of the shareholders of European Lithium which is scheduled to occur on October 22, 2026. The EUR Transaction is expected to be completed in November 2026.

 

On July 3, 2026, the Company entered into a deed to amend the SID with the principal changes being:

 

●EUR Shareholders and EUR Optionholders holding 50,000 or fewer EUR Shares or EUR Options (as applicable) on the record date will be given the option to participate in a sale facility whereby the CRML shares they would otherwise be entitled to under the Schemes will be sold on market by a sale agent and the EUR Shareholder or EUR Optionholder (as applicable) will instead receive the net sale proceeds of such sale;

 

●the CRML shares issued as Scheme consideration will be issued directly to EUR Shareholders and EUR Optionholders, rather than utilising a CHESS Depository Interest (CDI) structure as had been initially contemplated (and expressly reserved for further determination) under the terms of the May SID.

 

On August 19, 2026, the Company entered into a second deed to amend the SID with the principal changes being the introduction of a floating Share Scheme Transaction Ratio, subject to a cap and collar, replacing the previous fixed ratio of 0.035 New CRML Shares for each EUR Share whereby:

 

●the Share Scheme Transaction Ratio will be determined by reference to the Scheme VWAP, being the average daily VWAP of CRML Shares on NASDAQ over the 20 consecutive NASDAQ Trading Days ending on the second NASDAQ Trading Day before the Share Scheme Meeting;

 

●where the Scheme VWAP is at or below the Floor Price (US$8.00), the Maximum Share Scheme Transaction Ratio of 0.045 will apply;

 

●where the Scheme VWAP is at or above the Ceiling Price of US$16.00, the Minimum Share Scheme Transaction Ratio of 0.025 will apply; and

 

●where the Scheme VWAP is between US$8.00 and US$16.00, the Share Scheme Transaction Ratio will be calculated in accordance with the formula set out in the amended SID, with the ratio adjusting on a linear basis between 0.045 and 0.025.

 

In connection with the EUR Transaction, CRML intends to acquire 100% of EUR. As a result of the acquisition of EUR Transaction, CRML will acquire the remaining 7.5% minority interest held in Tanbreez a consolidated subsidiary of CRML, resulting in CRML holding a 100% ultimate ownership interest in Tanbreez and EUR.

 

Corporate Governance & Management

 

In connection with the asset acquisition in the EUR Transaction, the Company will replace existing share-based payment arrangements held by key management personnel (KMPs) of EUR with new equity-settled awards over the shares of CRML. 

 

Note 2 — Basis of Presentation

 

The accompanying unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, as amended by SEC Final Rule Release No. 33-10786, “Amendments to Financial Disclosures about Acquired and Disposed Businesses.”

 

The unaudited pro forma condensed combined balance sheet as of June 30, 2026, gives pro forma effect to the EUR Transaction as if they had been consummated on June 30, 2026. The unaudited pro forma condensed combined statements of operations for the fiscal year ended June 30, 2026, give pro forma effect to the transactions as if they had been consummated on July 1, 2025, the earliest period presented.

 

6

 

 

The historical financial statements of CRML, EUR have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The condensed combined pro forma financial information reflects IFRS and is presented in US Dollars (“USD”).

 

To prepare the pro forma financial information, the historical financial statements of EUR were originally reported using Australian Dollars (“AUD”) and have been translated into USD to conform to the reporting metrics of CRML:

 

The unaudited pro forma condensed combined financial information gives effect to the transaction under two potential consideration scenarios based on the exchange ratio range set forth in the SID:

 

  ● Minimum Consideration Scenario (Exchange Ratio: 0.025): Assumes the minimum share consideration is issued using an exchange ratio of 0.025 of ordinary shares for each European Lithium share. Under this scenario, a total of approximately 50,449,132 net ordinary shares (which include 2,250,000 shares issued for replacement performance rights) will be issued, representing an aggregate equity consideration of $781.16 million (based on an assumed price per share of $16.00 which is the lowest share price at which the 0.025 exchange ratio becomes applicable, the 0.025 exchange ratio applies if the VWAP is $16 or more).

 

  ● Maximum Consideration Scenario (Exchange Ratio: 0.045): Assumes the maximum share consideration is issued using an exchange ratio of 0.045 of ordinary shares for each European Lithium share. Under this scenario, a total of approximately 90,592,758 net Ordinary Shares (which include 4,050,000 shares issued for replacement performance rights) will be issued, representing an aggregate equity consideration of $702.31 million (based on an assumed price per share of $8.00 which is the highest share price at which the 0.045 exchange ratio becomes applicable, the 0.045 exchange ratio applies if the VWAP is $8 or less ).

 

The actual number of shares to be issued at closing will be determined based on the final exchange ratio specified in accordance with the SID upon consummation of the EUR Transaction.

 

On April 29, 2026, CRML completed the acquisition of a 50.5% ownership interest in Tanbreez Mining Greenland A/S (“Tanbreez”), which increased the CRML’s ownership in Tanbreez from 42% to 92.5%. The results of the operations of the CRML for the year ended June 30, 2026 included consolidation of the results of the operations of Tanbreez since April 29, 2026, as well as share of the losses of Tanbreez recorded under equity method of accounting for the period form July 1, 2025 to April 29, 2026 of $1,054,949. The amounts included in the column “Tanbreez (July 1, 2025 through April 29, 2026)” included in the pro-forma results of operations represent addition of results of the operations of Tanbreez for the period from July 1, 2025 through April 29, 2026.

 

The historical financial information has been adjusted to give pro forma effect to the EUR Transaction. The adjustments are presented to provide relevant information necessary for an accurate understanding of the combined company upon consummation. The pro forma information is for illustrative purposes only and is not necessarily indicative of the historical results that would have been achieved or the future results that the combined company will experience.

 

7

 

 

Note 3 — Accounting for the Asset Acquisitions

 

Basis of Consolidation and Control Assessment

 

In connection with the EUR Transaction, CRML’s intended acquisition of EUR will result in the Company acquiring the remaining 7.5% interest, bringing CRML’s total ownership of Tanbreez to 100%. In accordance with IFRS 10.23, changes in a parent’s ownership interest in a subsidiary that do not result in a loss of control are accounted for strictly as equity transactions (i.e., transactions with owners in their capacity as owners).

 

Consequently, the acquisition of the remaining 7.5% interest via EUR will not result in the recognition of a gain or loss in the statement of operations. Instead, the transaction will adjust the carrying amounts of the controlling interest and reduce the NCI balance to zero, reflecting CRML’s ultimate 100% ownership of Tanbreez and of EUR.

 

Accounting Acquirer Determination

 

CRML was determined to be the accounting acquirer under IFRS 10 and IFRS 3. While the application of IFRS 3 involves a higher level of judgement, an evaluation of the relative facts and circumstances favored CRML as the acquirer, specifically: relative voting rights post-transaction (Under the minimum consideration scenario CRML is anticipated to hold approximately 67% and EUR 33% and under the maximum consideration scenario CRML is anticipated to hold approximately 53% and EUR 47%), the composition of the combined governing body, the selection of senior executive management, the relative size of the entities, and underlying terms of exchange. Accordingly, EUR is treated as the accounting acquiree.

  

Measurement Basis and Asset/Equity Recognition

 

In accordance with IFRS 2, the EUR Transaction is measured based on the fair value of the identifiable assets acquired and liabilities assumed at the acquisition date. CRML recognizes these identifiable items at their acquisition-date fair values, including property, plant, and equipment (PP&E), cash and cash equivalents, and other investments. Equity instruments issued by the Company are recognized as an increase in equity, measured by reference to the fair value of the net assets acquired. Because IFRS 3 does not apply, no goodwill is recognized; total consideration is entirely allocated to the identifiable assets and liabilities based on their relative fair values, and transaction costs are capitalized as part of the initial asset cost basis.

 

Reciprocal Shareholding and Treasury Share Reclassification (IAS 32)

 

Prior to the transaction, EUR held an historical investment in CRML. While this investment is initially recognized at fair value as part of the assets acquired via the transaction, under IAS 32 (Financial Instruments: Presentation), an entity is prohibited from recognizing its own equity instruments as a financial asset. Accordingly, the historical CRML shares acquired from EUR are immediately reclassified as treasury shares and presented as a deduction from equity within the condensed combined financial statements, eliminating the reciprocal investment asset against equity.

 

Replacement Share-Based Payment Awards

 

As part of the EUR Transaction, the Company will replace existing share-based payment arrangements held by key management personnel (KMPs) of EUR with new equity-settled awards over the shares of CRML. 

 

While the EUR Transaction is an asset acquisition outside the scope of IFRS 3, the allocation and modification principles of IFRS 2 are applied to evaluate these replacement awards. The grant-date fair value of the replacement awards is allocated between historical acquisition consideration and post-acquisition employee compensation based on the proportion of the vesting period completed at the acquisition date:

 

  ● Pre-Acquisition Service Portion: The portion of the fair value attributable to service periods completed prior to the acquisition is capitalized and included in the cost basis of the assets acquired.

 

  ● Post-Acquisition Service Portion: The portion attributable to remaining vesting periods is recognized as employee compensation expense over the prospective post-acquisition service period.

 

8

 

 

In connection with the EUR Transaction, certain outstanding share-based payment awards of the EUR held by employees/grantees are being exchanged for replacement share-based payment awards of CRML. Although IFRS 2 is the applicable basis of accounting for the EUR transaction IFRS 3 paragraph B56-B62 are applied by analogy only. In accordance with IFRS 3 Business Combinations (specifically paragraphs 56–58 and B56–B62), the market-based measure of the replacement awards is allocated between consideration transferred for the acquiree (pre-combination service) and post-combination remuneration expense. Although the EUR Transaction does not fall under the scope of IFRS 3, as this is an asset acquisition, the principles under IFRS 3 were used to determine the accounting approach for the share-based payments awards replaced.

 

The table below sets forth, under each consideration scenario, (i) the number of replacement instruments issued, (ii) the fair value/market-based measure of the original and replacement awards, including the valuation date and valuation source/methodology, (iii) the allocation between consideration transferred and post-acquisition expense, and (iv) the amount of any incremental fair value:

 

Min Consideration Scenario

 

Tranche  Number of EUR performance rights   Fair value of original award at modification date (USD)   Number of CRML replacement awards   Fair value of replacement
(USD)
   Amount allocated to consideration   Amount allocated to post-acquisition expense   Incremental value of the replacement awards 
A   45,000,000    3,164,740    1,125,000    18,000,000    2,059,467    15,940,533    14,835,260 
B   45,000,000    6,103,881    1,125,000    18,000,000    2,077,405    15,922,595    11,896,119 
C   45,000,000    5,344,471    1,125,000    3,128,175    1,818,946    1,309,229    (2,216,296)
D   45,000,000    6,447,046    1,125,000    4,332,375    1,484,253    2,848,122    (2,114,671)
E   45,000,000    6,053,042    1,125,000    4,003,650    1,393,545    2,610,105    (2,049,392)
F   45,000,000    6,523,305    1,125,000    4,794,188    1,135,441    3,658,747    (1,729,117)
Total   270,000,000    33,636,485    6,750,000    52,258,388    9,969,057    42,289,331    18,621,903 

 

Max Consideration Scenario

 

Tranche  Number of EUR performance rights   Fair value of original award at modification date (USD)   Number of CRML replacement awards   Fair value of replacement
(USD)
   Amount allocated to consideration   Amount allocated to post-acquisition expense   Incremental value of the replacement awards 
A   45,000,000    3,164,740    2,025,000    16,200,000    2,059,467    14,140,533    13,035,260 
B   45,000,000    6,103,881    2,025,000    16,200,000    2,077,405    14,122,595    10,096,119 
C   45,000,000    5,344,471    2,025,000    9,539,775    1,818,946    7,720,829    4,195,304 
D   45,000,000    6,447,046    2,025,000    10,616,265    1,484,253    9,132,012    4,169,219 
E   45,000,000    6,053,042    2,025,000    10,054,328    1,393,545    8,660,783    4,001,286 
F   45,000,000    6,523,305    2,025,000    10,830,105    1,135,441    9,694,664    4,306,800 
Total   270,000,000    33,636,485    12,150,000    73,440,473    9,969,057    63,471,416    39,803,988 

 

Purchase Price Allocation (PPA) – Min Consideration Scenario

 

The fair value of EUR’s identifiable net assets was determined as follows:

 

(In shares) Minimum   EUR  
EUR shares currently on issue     1,726,231,616  
EUR listed options     199,550,870  
EUR unlisted options     2,182,787  
EUR performance rights     90,000,000  
Total     2,017,965,273  
         
Exchange ratio     0.0250  
EUR shareholders to be issued shares in CRML     50,449,132  

 

9

 

 

(In USD thousands)   Est Fair
Value
 
Consideration:        
Shares issues 50,449,132 (1)(2)   $ 781,155  
Total Consideration Paid   $ 781,155  
         
Cash & Cash Equivalents   $ 204,162  
Trade and other receivables     1,284  
Prepaid expenses     44  
Indemnification Assets     1,181  
Short term loan receivables     6,622  
Convertible note     4,584  
Restricted cash and other deposits     39  
Property Plant & Equipment     1  
Listed and unlisted investments     21,782  
Investment in associates     31,329  
Investment in Tanbreez     24,069  
Investment in CRML     728,581  
Long term loan receivable     804  
Total Assets Acquired     1,024,482  
Liabilities Assumed     (3,400 )
Net Assets Acquired   $ 1,021,082  
         
Difference allocated to share capital   $ 239,927  

 

(1) Includes 48,199,132 shares valued at $16.00 based on the assumed price per share of $16.00 which is the lowest share price at which the 0.025 exchange ratio becomes applicable for estimated fair value of $771,186,109.
   
(2) Includes the portion of replacement rights that is part of the consideration. The portion of the replacement rights that is part of the consideration is determined based on the fair value of the original grant at acquisition date and the services provided up till acquisition date which is valued at $9,969,057.

 

Under the minimum consideration scenario, the fair value of net assets exceeds the fair value of consideration by $239,926,974. IFRS 2 does not address the accounting for this scenario. However, under IFRS 9 Financial Instruments, financial assets must be recognized at their fair values on initial recognition. Normally, any day 1 losses for financial assets with quoted prices are recognized in profit or loss immediately. However, a significant portion of the assets acquired being 71% of the assets being acquired is CRML’s own shares, the excess of fair value of net assets acquired have been recognized in equity.

 

10

 

 

Purchase Price Allocation (PPA) – Max Consideration Scenario

 

The fair value of EUR’s identifiable net assets was determined as follows:

 

(In shares) Maximum   EUR  
EUR shares currently on issue     1,726,231,616  
EUR listed options     194,797,880  
EUR unlisted options     2,142,904  
EUR performance rights     90,000,000  
Total     2,013,172,400  
         
Exchange ratio     0.0450  
EUR shareholders to be issued shares in CRML     90,592,758  

 

(In USD thousands)  Est Fair
Value
 
Consideration:     
Shares issues 90,592,758 (1)(2)  $702,311 
Total Consideration Paid  $702,311 
      
Cash & Cash Equivalents  $204,162 
Trade and other receivables   1,284 
Prepaid expenses   44 
Indemnification Assets   1,181 
Short term loan receivables   6,622 
Convertible note   4,584 
Restricted cash and other deposits   39 
Property Plant & Equipment   1 
Listed and unlisted investments   21,782 
Investment in associates   31,329 
Investment in Tanbreez   24,069 
Investment in CRML   364,291 
Long term loan receivable   804 
Total Assets Acquired   660,192 
Liabilities Assumed   (3,400)
Net Assets Acquired  $656,792 
      
Difference recognized as day 1 loss  $(45,519)

 

(1) Includes 86,542,758 shares valued at $8.00 based on the assumed price per share of $8.00 which is the highest share price at which the 0.045 exchange ratio becomes applicable for estimated fair value of $692,342,064.
(2) Includes the portion of replacement rights that is part of the consideration. The portion of the replacement rights that is part of the consideration is determined based on the fair value of the original grant at acquisition date and the services provided up till acquisition date which is valued at $9,969,057.

 

Under the maximum consideration scenario, the fair value of consideration exceeds the fair value of net assets by $45,519,685.

 

The difference between the total consideration paid less the net assets acquired is recognized in profit or loss in accordance with IFRS 2.13A.

 

11

 

 

Note 4 — EUR Conversion and Presentation Alignment from AUD to USD

 

The historical financial information of EUR has been prepared in Australian Dollars (AUD) and is being converted to US Dollars (USD) for the purposes of the unaudited pro forma condensed consolidated financial information to conform with the historical financial information of CRML.

 

As of June 30, 2026 (in thousands)  IFRS
before
conversion
(in AUD)
   AUD to USD
Exchange
Rate as of
June 30,
2026
   IFRS
after
conversion to
(in USD)
 
ASSETS            
Current assets:               
Cash  $296,295    0.68905   $204,162 
Trade and other receivable   1,864    0.68905    1,284 
Prepaid expenses   64    0.68905    44 
Indemnification assets   1,714    0.68905    1,181 
Short Term Loans Receivable   9,610    0.68905    6,622 
Derivative asset   6,652    0.68905    4,584 
Total current assets   316,199    0.68905    217,877 
Listed and unlisted investments   31,612    0.68905    21,782 
Investment in associate   45,466    0.68905    31,328 
Investment in Tanbreez   10,416    0.68905    7,177 
Investment in CRML   676,938    0.68905    466,444 
Property, plant and equipment   1    0.68905    1 
Restricted cash and other deposits   57    0.68905    39 
Long-term loans receivable   1,166    0.68905    804 
Total assets  $1,081,855        $745,452 
LIABILITIES               
Current liabilities:               
Accounts payable and accrued liabilities  $3,101    0.68905   $2,137 
Lease liability   2    0.68905    1 
Total current liabilities   3,103    0.68905    2,138 
Long term lease liability   1    0.68905    1 
Deferred tax liability   1,830    0.68905    1,261 
Total liabilities   4,934    0.68905    3,400 
Net assets  $1,076,921        $742,052 
EQUITY               
Share capital   104,839         66,474 
Reserves   (22,284)        (7,040)
Noncontrolling interest   (1)        (1)
Retained earnings   994,367         682,619 
Total equity  $1,076,921        $742,052 

 

12

 

 

For the Year Ended June 30, 2026 (in thousands)   IFRS
before
conversion
(in AUD)
    AUD to USD
Average
Exchange Rate for the
year ended
June 30,
2026
    IFRS
after
conversion to
(USD)
 
Other income   $ 7,917       0.6777     $ 5,365  
Operating expenses                        
Fair value gain     6,652       0.6777       4,509  
Net loss on disposals and deemed disposal of shares     (20,357 )     0.6777       (13,796 )
Gain on deconsolidation     1,275,503       0.6777       864,396  
Gain on deconsolidation - recycling of FX     2,581       0.6777       1,749  
Employee benefits expense     (580 )     0.6777       (393 )
Depreciation and amortization expense     (2 )     0.6777       (1 )
Depreciation and amortization expense – leased assets     (26 )     0.6777       (18 )
Finance expenses     (4,471 )     0.6777       (3,030 )
Exploration expenditure expensed     (184 )     0.6777       (125 )
Exploration expenditure impairment     (829 )     0.6777       (562 )
Consulting fees     (7,759 )     0.6777       (5,258 )
Travel expenses     (278 )     0.6777       (189 )
Regulatory and compliance costs     (851 )     0.6777       (577 )
Gain on fair value of financial assets through profit or loss     12,086       0.6777       8,191  
Share based payment expense     (10,610 )     0.6777       (7,190 )
Share of net losses of associate accounted for using the equity method     (129,319 )     0.6777       (87,639 )
Merger expenses     (1,225 )     0.6777       (830 )
Gain/(loss) on extinguishment of liability     (103 )     0.6777       (70 )
Foreign exchange gain/(loss)     (15,889 )     0.6777       (10,768 )
Administration expenses     (1,395 )     0.6777       (945 )
Promotion / IR / PR     (258 )     0.6777       (175 )
Insurance     (181 )     0.6777       (123 )
Impairment of convertible notes     698       0.6777       473  
Impairment of investment in associates     (163,086 )     0.6777       (110,522 )
Occupancy     (2 )     0.6777       (1 )
Share of CRML expenses for the period to deconsolidation     (15,703 )     0.6777       (10,642 )
Other expense     93       0.6777       63  
Profit/(loss) before income tax     932,422               631,892  
Income tax expense     (1,831 )     0.6777       (1,241 )
Profit/(loss) after tax from continuing operations    $ 930,591             $  630,651  
Other comprehensive loss     (53,344 )     0.6777       (36,151 )
Total comprehensive income   $ 877,247             $ 594,500  

 

13

 

 

Note 5 — Adjustments to Unaudited Pro Forma

 

Condensed Combined Balance Sheet as of June 30, 2026

 

The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:

 

EUR Transaction Accounting Adjustments

 

  A. Reflects the financial effects of the closing of the EUR Transaction and the transition to full consolidation of the underlying net assets. Management evaluated the acquisition under IFRS 3 Business Combinations and concluded that the acquired entity did not constitute a business, as it lacked substantive processes and outputs. Accordingly, the transaction has been accounted for as an asset acquisition settled through the issuance of equity instruments within the scope of IFRS 2 Share-based Payment.   In accordance with IFRS 2, the transaction was measured based on the fair value of the identifiable net assets received, assuming the transaction closed on June 30, 2026. The accounting mechanics and consolidation adjustments are applied as follows:  

 

Minimum Consideration

 

  ● Equity Consideration: Initial share consideration consists of 50,449,132 ordinary shares (which include 2,250,000 shares issued for replacement performance rights) with an implied contract value of $781.16 million. IFRS 2 does not address the accounting for this scenario where the net assets acquired is greater than the fair value of the consideration paid. However, under IFRS 9 Financial Instruments, financial assets must be recognized at their fair values on initial recognition. Normally, any day 1 losses for financial assets with quoted prices are recognized in profit or loss immediately. However, a significant portion of the assets acquired being 71% of the assets being acquired is CRML’s own shares, the excess of fair value of net assets acquired have been recognized in equity. Consequently, the share capital credit was adjusted by $239.93 million to match the $1,021.08 million net asset valuation.

 

  ● Elimination of Historical Equity and Non-Controlling Interest: To reflect the capital structure of the combined legal entity and avoid double-counting, the historical equity accounts of the acquired entity were eliminated upon consolidation, including Share Capital of $66.47 million, Reserves of $7.04 million, and retained earnings of $682.62 million. Additionally, the historical non-controlling interest of $1 held by European Lithium Limited (“EUR”) was eliminated to reflect that the entity is now a 100%-owned, fully consolidated subsidiary of the Company.

 

Maximum Consideration

 

  ● Equity Consideration: Initial share consideration consists of 90,592,758 ordinary shares (which include 4,050,000 shares issued for replacement performance rights)with an implied contract value of $702.31 million. Because the fair value of the identifiable net assets acquired was determined to be $656.80 million, the transaction value was measured by reference to the fair value of the assets received in accordance with IFRS 2.13A. Consequently, the amount of $45.52 million was expensed as day 1 loss on acquisition.

 

  ● Elimination of Historical Equity and Non-Controlling Interest: To reflect the capital structure of the combined legal entity and avoid double-counting, the historical equity accounts of the acquired entity were eliminated upon consolidation, including Share Capital of $66.47 million, Reserves of $7.04 million, and retained earnings of $682.62 million. Additionally, the historical non-controlling interest of $1 held by European Lithium Limited (“EUR”) was eliminated to reflect that the entity is now a 100%-owned, fully consolidated subsidiary of the Company.

 

  B. Reflects the elimination of the EUR held historical investment in CRML. While this investment is initially recognized at fair value as part of the assets acquired via the transaction, under IAS 32 (Financial Instruments: Presentation), an entity is prohibited from recognizing its own equity instruments as a financial asset. Accordingly, the historical CRML shares acquired from EUR are immediately reclassified as treasury shares and presented as a deduction from equity within the condensed combined financial statements, eliminating the reciprocal investment asset against equity.  
     
  C. Reflects the elimination of both the NCI held by CRML in Tanbreez and the EUR investment in the Tanbreez. According to IFRS 10.B96, any difference between the consideration paid (the book value of the investment in the acquired entity) and the carrying amount of the NCI adjusted must be recognized directly in equity (attributable to the parent).  

 

  D. Reflects the elimination of intercompany loan balances between EUR, Tanbreez, and CRML, comprising a $5.67 million short-term receivable/payable and a $0.80 million long-term receivable/payable. The adjustment also includes the recognition of $4,210 in foreign exchange translation reserves resulting from currency translation differences between EUR (denominated/presented in AUD) and CRML (presented in USD).

  

14

 

 

Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for Year Ended June 30, 2026

 

The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:

 

EUR Transaction Accounting Adjustments 

 

(AA)To remove the impact of CRML non-controlling interest carried on EUR and Tanbreez non-controlling interest carried on CRML.

 

(BB)To eliminate $643.55 million of historical net gains, representing gains on deconsolidating of $866.15 million (gain on deconsolidation – recycling of FX translation reserves of $1.75 million and gain on deconsolidation of CRML of $864.40 million), less losses and expenses of $222.60 million (historical equity-method share of loss of $87.6 million, investment impairments of $110.5 million, net loss on disposal of shares of $13.80 million, CRML expenses pre deconsolidation of $10.64 million). Following the EUR Transaction, CRML is fully consolidated into the financial results of the Combined Company. Accordingly, EUR’s historically recognized gains/losses, are eliminated to prevent double-counting of CRML’s historical operating losses, which are already directly included within CRML’s historical financial statements.

 

(CC)To recognize share-based compensation related to the EUR performance rights replaced with CRML performance rights that vested immediately upon acquisition date, and the first 12 months of post-acquisition expense for Tranches C – F replacement warrants. To avoid double counting, the share-based payment expense of $7,190,330 recognized in EUR for these share-based payment awards have been reversed.

 

Minimum consideration scenario

  

Tranche   Issued     Date of issue     Condition   Original Vesting Period (Days)     Modified terms   FV of Replacement Awards US$     Amount allocated to purchase consideration     Amount to be expensed in the first 12 months  
A     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.50 before 31 December 2026     398     Cancelled and replaced with 1,125,000 CRML ordinary shares vesting immediately upon acquisition date     18,000,000      2,059,467    15,940,533  
B     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.60 before 31 December 2027     761     Cancelled and replaced with 1,125,000 CRML ordinary shares vesting immediately upon acquisition date     18,000,000     2,077,405     15,922,595  
C     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.70 before 31 December 2027     761     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ US$13.386before 31 December 2027      3,128,175     1,818,946     833,146  
D     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.80 before 31 December 2028     1,125     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ U$15.298 before 31 December 2028      4,332,375     1,484,253     1,051,715  
E     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.90 before 31 December 2028     1,125     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ U$17.210 before 31 December 2028      4,003,650     1,393,545     963,823  
F     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $1.00 before 31 December 2029     1,488     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ US $19.123 before 31 December 2029      4,794,188     1,135,441     952,398  
Total     270,000,000                              52,258,388     9,969,057     35,664,210  

 

15

 

 

Maximum consideration scenario

 

Tranche   Issued     Date of issue     Condition   Original Vesting Period (Days)     Modified terms   FV of Replacement Awards
US$  
    Amount allocated to purchase consideration     Remaining amount to be expensed in the first
12 months
 
A     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.50 before 31 December 2026     398     Cancelled and replaced with 2,025,000 CRML ordinary shares vesting immediately upon acquisition date     16,200,000       2,059,467       14,140,533  
B     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.60 before 31 December 2027     761     Cancelled and replaced with 2,025,000 CRML ordinary shares vesting immediately upon acquisition date     16,200,000       2,077,405   `   14,122,595  
C     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.70 before 31 December 2027     761     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ US$13.386before 31 December 2027     9,539,775       1,818,946       4,913,255  
D     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.80 before 31 December 2028     1,125     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ U$15.298 before 31 December 2028     10,616,265       1,484,253       3,372,142  
E     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $0.90 before 31 December 2028     1,125     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ U$17.210 before 31 December 2028     10,054,328       1,393,545       3,198,133  
F     45,000,000     26/11/2025     EUR VWAP for 20 consecutive days ≥ $1.00 before 31 December 2029     1,488     1,575,000 CRML performance rights; VWAP for 20 consecutive days ≥ US $19.123 before 31 December 2029     10,830,105       1,135,441       2,523,591  
Total                                   73,440,473       9,969,057       42,270,249  

 

(DD)To recognize day 1 loss on acquisition under the maximum consideration scenario as the fair value of the shares are estimated to be greater than the fair value of the net assets acquired of $45.52 million.

 

(EE)To eliminate the share of the losses of Tanbreez recorded by the European Lithium under equity method of accounting for the year ended June 30, 2026 as column “Tanbreez” in the pro formas includes the additional operation for the period from July 1, 2026 through April 29, 2026.

 

16

 

 

Note 6 — Net Earnings (Loss) per Share

 

Represents the earnings (loss) per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the EUR Transaction, net of the CRML shares held by EUR which are treasury shares, assuming the net shares were outstanding since July 1, 2025. The impact of the EUR Transaction is being reflected as if it had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted earnings (loss) per share assumes that the shares issued in connection with the EUR Transaction have been outstanding for the entire period presented.

 

The following table sets out the share ownership of CRML following the issuance of shares as the estimated issuance of shares under the minimum consideration and maximum consideration of 50,449,132 share and 90,592,758 share, respectively, for the EUR Transaction on a pro forma basis: (for the year ended June 30, 2026)

   

Net loss per share  Year Ended
June 30,
2026 (Minimum)
   Year Ended
June 30,
2026 (Maximum)
 
         
Net loss attributed to CRML  $(271,158,764)  $(323,284,488)
Weighted average shares outstanding – Pro forma basic and diluted   127,218,426    167,362,052 
           
Net loss per share – Basic  $(2.13)  $(1.93)
Net loss per share - Diluted  $(2.13)  $(1.93)

 

Weighted Average Shares Outstanding   Year Ended
June 30,
2026 (Minimum)
    Year Ended
June 30,
2026 (Maximum)
 
             
Historical weighted average shares for the year ended June 30, 2026     122,305,632       122,305,632  
CRML shares held by EUR as treasury shares     (45,536,338 )     (45,536,338 )
EUR shares issued     50,449,132       90,592,758  
Pro-forma weighted average shares outstanding     127,218,426       167,362,052  

 

17